All the news Showing 10 of 47 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Bulevirtide leads to sustained improvement for people with hepatitis D Liz Highleyman / 28 June 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... Bulevirtide for hepatitis D proves effective in real-world studies Liz Highleyman / 25 January 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load and improved liver enzyme levels in real-world studies in France and Austria, according to findings presented ... Hepatitis B may increase cancer risk in people with HIV Keith Alcorn / 29 December 2021 People with both HIV and hepatitis B have a higher rate of non-liver cancers compared to other people with HIV, a large European study has found. The study investigators, who have published ... People with liver cirrhosis have weaker responses to the Pfizer and Moderna SARS-CoV-2 vaccines Keith Alcorn / 16 November 2021 People with cirrhosis of the liver had delayed and suboptimal responses to the Pfizer or Moderna SARS-CoV-2 vaccines compared to healthy adults, an Italian study has found. People with decompensated cirrhosis had significantly ... Bulevirtide appears safe and effective for hepatitis D Liz Highleyman / 28 June 2021 The entry inhibitor bulevirtide (Hepcludex) suppressed hepatitis delta viral load and improved liver enzyme levels in a phase III clinical trial, according to late-breaking study results presented this week at the 2021 International Liver ... Fatty liver disease common in people living with HIV and hepatitis B Keith Alcorn / 30 September 2020 Around one in three people with HIV and hepatitis B had fatty liver disease and one in ten had liver damage, US researchers from the Hepatitis B Research Network report in Clinical ... Bulevirtide shows promise as maintenance therapy for hepatitis D Liz Highleyman / 30 August 2020 High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ... Combination therapies show promise against hepatitis D Liz Highleyman / 16 December 2019 Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ... US doctors failing to diagnose hepatitis C years after first signs of cirrhosis Keith Alcorn / 23 August 2019 Doctors are failing to test for hepatitis C in up to one in five people who have advanced liver disease despite many years of medical care, and these people are more likely ... Faecal transplants improve encephalopathy in people with advanced liver disease Liz Highleyman / 24 April 2019 Faecal microbiota transplantation (FMT), which helps restore a healthy mix of bacteria in the gut, can help reverse brain function impairment in people with liver failure, according to a report at the International ... ← First12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive